Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink

被引:4
|
作者
Eyles, Emily [1 ,2 ,5 ]
Margelyte, Ruta [1 ,2 ]
Edwards, Hannah B. [1 ,2 ]
Moran, Paul A. [2 ]
Kessler, David S. [2 ]
Davies, Simon J. C. [2 ,3 ]
Bolea-Alamanac, Blanca [4 ]
Redaniel, Maria Theresa [1 ,2 ]
Sullivan, Sarah A. [2 ]
机构
[1] Univ Hosp Bristol & Weston NHS Fdn Trust, Natl Inst Hlth Res Appl Res Collaborat West NIHR A, Bristol, England
[2] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[3] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[4] Univ Toronto, Womens Coll Hosp, Toronto, ON, Canada
[5] 9th Floor,Whitefriars, Bristol BS1 2NT, England
关键词
antipsychotics; hyperlipidemia; hypertension; diabetes; CPRD; time-varying; 2ND-GENERATION; MORTALITY; UPDATE; TRIAL;
D O I
10.1093/schbul/sbad126
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background and Hypothesis Antipsychotics are first-line drug treatments for schizophrenia. When antipsychotic monotherapy is ineffective, combining two antipsychotic drugs is common although treatment guidelines warn of possible increases in side effects. Risks of metabolic side effects with antipsychotic polypharmacy have not been fully investigated. This study examined associations between antipsychotic polypharmacy and risk of developing diabetes, hypertension, or hyperlipidemia in adults with schizophrenia, and impact of co-prescription of first- and second-generation antipsychotics. Study Design A population-based prospective cohort study was conducted in the United Kingdom using linked primary care, secondary care, mental health, and social deprivation datasets. Cox proportional hazards models with stabilizing weights were used to estimate risk of metabolic disorders among adults with schizophrenia, comparing patients on antipsychotic monotherapy vs polypharmacy, adjusting for demographic and clinical characteristics, and antipsychotic dose. Study Results Median follow-up time across the three cohorts was approximately 14 months. 6.6% developed hypertension in the cohort assembled for this outcome, with polypharmacy conferring an increased risk compared to monotherapy, (adjusted Hazard Ratio = 3.16; P = .021). Patients exposed to exclusive first-generation antipsychotic polypharmacy had greater risk of hypertension compared to those exposed to combined first- and second-generation polypharmacy (adjusted HR 0.29, P = .039). No associations between polypharmacy and risk of diabetes or hyperlipidemia were found. Conclusions Antipsychotic polypharmacy, particularly polypharmacy solely comprised of first-generation antipsychotics, increased the risk of hypertension. Future research employing larger samples, follow-up longer than the current median of 14 months, and more complex methodologies may further elucidate the association reported in this study.
引用
收藏
页码:447 / 459
页数:13
相关论文
共 50 条
  • [41] Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink
    Clarson, Lorna E.
    Hider, Samantha L.
    Belcher, John
    Heneghan, Carl
    Roddy, Edward
    Mallen, Christian D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (04) : 642 - 647
  • [42] Ethnicity and risk of diagnosed dementia after stroke: a cohort study using the Clinical Practice Research Datalink
    Shiekh, Suhail Ismail
    Forbes, Harriet
    Mathur, Rohini
    Smeeth, Liam
    Pearce, Neil
    Warren-Gash, Charlotte
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2020, 74 (02) : 114 - 119
  • [43] Risk equations for prosthetic joint infections (PJIs) in UK: a retrospective study using the Clinical Practice Research Datalink (CPRD) AURUM and GOLD databases
    Perni, Stefano
    Prokopovich, Polina
    BMJ OPEN, 2024, 14 (05):
  • [44] Characteristics of people with type 1 diabetes in the UK: results of a 5-year cohort study using data from the Clinical Practice Research Datalink
    Choudhary, P.
    Wilmot, E.
    Baxter, M.
    Leelarathna, L.
    Afonso, M.
    Gupta, R. Shah
    Pulikottil-Jacob, R.
    Zhou, F. L.
    DIABETOLOGIA, 2019, 62 : S182 - S183
  • [45] Costs of gastrointestinal bleeding events in atrial fibrillation: a UK Clinical Practice Research Datalink study
    Ramagopalan, Sreeram, V
    Samnaliev, Mihail
    Weir, Sharada
    Sammon, Cormac J.
    Carroll, Robert
    Alikhan, Raza
    FUTURE CARDIOLOGY, 2019, 15 (05) : 367 - 375
  • [46] Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study
    Muller, Sara
    Bailey, James
    Bajpai, Ram
    Helliwell, Toby
    Harrisson, Sarah A.
    Whittle, Rebecca
    Mallen, Christian D.
    Ashworth, Julie
    PAIN, 2024, 165 (10) : 2282 - 2290
  • [47] Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study
    Thompson, Andrew
    Ashcroft, Darren M.
    Owens, Lynn
    van Staa, Tjeerd P.
    Pirmohamed, Munir
    PLOS ONE, 2017, 12 (03):
  • [48] The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink
    Ferguson, Samara
    Tepie, Maurille Feudjo
    Taylor, Andrew
    Roddam, Andrew
    Critchlow, Cathy
    Iqbal, Mazhar
    Spangler, Leslie
    Bayly, Jonathan
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2016, 22 (01) : 31 - 39
  • [49] Risk of Seizures Among Patients with Schizophrenia as Compared to the General Population in the Clinical Practice Research Datalink (CPRD)
    Jones, Meghan
    Swain, Jonathan
    DeLisle, Frank
    Kryzhanovskaya, Ludmila
    Kinon, Bruce J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 401 - 402
  • [50] Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink
    Cardwell, Chris R.
    Flahavan, Evelyn M.
    Hughes, Carmel M.
    Coleman, Helen G.
    O'Sullivan, Joe M.
    Powe, Des G.
    Murray, Liam J.
    CANCER CAUSES & CONTROL, 2014, 25 (01) : 33 - 43